ECHO 4 PWS: Sleep
When: RESCHEDULED
Tuesday, April 23, 2024 at 6:00 PM EST
Where: Virtual/Zoom Video
This series is for healthcare providers only
Register for our next ECHO 4 PWS webinar, “Sleep with Dr. Amee Revana,” at the button below.
PWSA | USA's - ECHO 4 PWS Health Care Provider Series
PWSA | USA launched our new Health Care Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to health care professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.
Our next healthcare ECHO topic will focus on Sleep and PWS presented by Amee Revana, DO FAASM, Associate Professor of Pediatrics, Texas Children’s Hospital, followed by a 20-minute case study on PWS (speaker to be determined).
PWSA | USA’s Health Care Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.
While this ECHO series is only for health care providers to attend, recordings of the webinars are available for our PWS families to view HERE.
Be on the lookout for more details about future ECHO 4 PWS webinar opportunities.
Speaker
Amee Revana, DO FAASM, Associate Professor of Pediatrics, Texas Children’s Hospital
LEarn More about PWS Research
Harmony Biosciences Initiates TEMPO PWS Study
Harmony Biosciences Holdings, Inc. is seeking participants for its TEMPO study, a global Phase 3 trial investigating pitolisant as a potential treatment for excessive daytime sleepiness (EDS) in individuals aged six years and older with Prader-Willi syndrome (PWS). Pitolisant is a medication that could help manage sleepiness and behavioral issues in people with PWS. There […]
New PWS Clinical Study: Free Informational Webinar with Harmony Biosciences
Join PWSA | USA and the team from Harmony Biosciences on Tuesday, March 12th at 8:00 p.m. EST / 5:00 p.m. PST to learn more about the upcoming Phase 3 registrational TEMPO study, a randomized, double-blind, placebo-controlled, multicenter, global clinical study that will further assess the safety and efficacy of pitolisant in patients with PWS, […]
Pitolisant Receives Orphan Drug Designation
Pitolisant from Harmony Biosciences Receives Orphan Drug Status from FDA for Treatment of PWS The FDA has granted Orphan Drug status to pitolisant, the trial drug from Harmony Biosciences to treat excessive daytime sleepiness (EDA) and behavioral disturbances. The designation shows that the FDA considers pitolisant to be a promising treatment for people with PWS. […]